+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Age: 18Years +All GendersPhase 2Phase 3
61 locations
S

Actively Recruiting

Researchers are studying patients with hypercholesterolaemia who either have a history of clinical atherosclerotic cardiovascular disease ASCVD or are at increased risk for a first ASCVD event. The trial aims to evaluate the effect on low-density lipoprotein-cholesterol LDL-C and the safety and tolerability of a fixed dose combination FDC of laroprovstatrosuvastatin compared to rosuvastatin alone. This is a Phase III randomized, double-blind, parallel-group study sponsored by AstraZeneca. Participants will be assigned to one of several groups receiving daily oral doses of laroprovstatrosuvastatin or rosuvastatin alone at different dose levels. Each laroprovstatrosuvastatin dose group is paired with a matching placebo to maintain blinding. The treatments are given daily over a period of 8 weeks to assess their effects on cholesterol levels. During the study, participants will undergo assessments to measure changes in LDL-C as the primary outcome at 8 weeks, along with secondary measures including Apo B, non-HDL cholesterol, and total cholesterol. Safety and tolerability will also be monitored throughout the treatment. Participants will have scheduled visits during the treatment period to ensure adherence and collect data, with the overall study completion projected by May 2027.

Age: 18Years - 130YearsAll GendersPhase 3
45 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 in people who have excess body weight and knee osteoarthritis. This study compares two doses of NNC0487-0111 given as weekly injections under the skin against a placebo, with the goal of helping participants lose weight and reduce knee pain. Participants have knee osteoarthritis confirmed by clinical and radiographic criteria and will follow a reduced-calorie diet and increased physical activity throughout the study. Participants will be randomly assigned to receive one of three treatments NNC0487-0111 dose level 1, NNC0487-0111 dose level 2, or a placebo, all given once weekly by subcutaneous injection using a pre-filled pen injector. The injections will be administered to the thigh, abdomen, or upper arm. All participants will be encouraged to follow a reduced-calorie diet and increase physical activity during the trial. The treatment period lasts for 80 weeks. Throughout the study, participants will have regular assessments of body weight, knee pain, physical function, and other health measures. Researchers will collect data on changes in weight, knee pain scores using the WOMAC index, physical function, blood pressure, cholesterol levels, blood sugar markers, and use of pain medication. Safety will be monitored through reporting of adverse events. The study is expected to continue until August 2028, with visits and evaluations occurring at scheduled intervals during the treatment period.

Age: 18Years +All GendersPhase 3
82 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of EB06, a monoclonal antibody, compared with placebo in adults who have moderate to severe non-segmental vitiligo. Vitiligo is a chronic autoimmune skin condition where skin loses pigmentation due to melanocyte destruction. EB06 targets CXCL10, a protein involved in the immune process that damages skin pigment cells, which is linked to the start and persistence of vitiligo patches. Participants receive EB06 through an intravenous infusion starting with a loading dose of 20 mgkg, followed by maintenance doses of 10 mgkg. The study randomly assigns adults to either the EB06 group or a placebo group in a parallel, double-blind design. The main treatment period lasts 28 weeks, during which researchers monitor the impact on skin pigmentation and safety outcomes. During the study, participants undergo regular assessments including skin evaluations using the Facial Vitiligo Area Scoring Index F-VASI at Week 28 as the primary outcome, with additional measures at Weeks 24 and 32. Other evaluations include body surface area affected, patient global impressions, and investigator assessments. Safety and tolerability are also closely monitored throughout the treatment period. The total study duration extends until December 2027, providing a comprehensive view of EB06s effects on vitiligo.

Age: 18Years +All GendersPhase 2
4 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the effects of AZD6234 as an additional treatment alongside incretin-based therapies in adults who are overweight or have obesity with at least one weight-related health condition, with or without Type 2 Diabetes Mellitus. This Phase III global study will compare how well AZD6234 works against a placebo by measuring changes in body weight over 68 weeks. Participants will be randomly assigned to receive either AZD6234 or a matching placebo, both given as weekly injections under the skin. These treatments will be added to their stable dose of existing incretin-based medications. The study is designed to monitor participants for 68 weeks of treatment to assess the impact on body weight and related health measures. During the study, participants will undergo regular assessments including body weight measurements, waist circumference, blood pressure, blood tests for triglycerides and HbA1c, and evaluation of weight loss milestones. Safety and effectiveness will be closely monitored throughout the treatment period, which lasts about 68 weeks. The study aims to provide detailed information on how AZD6234 affects weight and metabolic health in this population.

Age: 18Years +All GendersPhase 3
96 locations

1-10 of 25

1